A robust antibiotic portfolio with communication to physicians, in line with guidelines.
We at Lupin strive to bring novel anti-infectives to India through various tie-ups. We continuously address infectious diseases through a comprehensive, science-driven approach.
A robust antibiotic portfolio with communication to physicians, in line with guidelines.
Implementation of antimicrobial stewardship programs that promote rational prescribing and diagnostics.
Continuous education initiatives for healthcare providers to improve awareness of AMR risks and optimize treatment protocols.
We address a wide spectrum of infectious diseases across key therapeutic segments.
Includes serious and common infections such as
Focused on diseases caused by organisms such as
Addressing diseases such as
Disclaimer: The content on this website/webpage relates to a specific therapy/therapeutic area and is intended solely for informational and educational purposes for healthcare professionals and patients across India and other global locations, is not intended to substitute professional medical advice, diagnosis, or treatment. Advice from a physician or other qualified healthcare professional must be sought for any queries regarding a medical condition or treatment. Information on this website/webpage should not be solely used or relied upon in the absence of or delay in receiving professional medical advice. While Lupin makes reasonable efforts to ensure that the information is accurate and up to date, it makes no representations or warranties regarding its completeness or accuracy and accepts no liability for reliance on such information. The information on this website/webpage is not a substitute for prescribing information or patient information leaflets accompanying any medicinal product. The information on this website/webpage is subject to change without notice and may not reflect the most current medical, scientific, or regulatory developments. All content on this website/webpage is the intellectual property of Lupin and shall not be reproduced, modified, distributed, or used for any commercial purpose without the prior written consent of Lupin.
Our anti-infective portfolio is among the most comprehensive in India, covering oral and injectable therapies across various diseases.
Our flagship brand and market leader in the cephalosporin segment, CETIL (cefuroxime-based formulations) for over 25 years.
A third-generation oral cephalosporin (cefpodoxime-based) antibiotic, DOXCEF is used for mild to moderate infections.
A carbapenem-based (meropenem) injectable antibiotic, MEROTROL is used for severe and multidrug-resistant infections.
A combination of piperacillin and tazobactam, TAZAR is designed to combat resistant infections.
Cefadroxil-based formulations for bacterial infections.
Levofloxacin-based therapies for respiratory infections.
These brands are also available in multiple dosage forms including tablets, suspensions, and injectables.
We have built a strong anti‑infective legacy through sustained leadership, portfolio depth, patient impact, and a continued commitment to responsible antibiotic use.
As infectious diseases continue to evolve, so does the challenge of antimicrobial resistance. At Lupin, we remain committed to strengthening our anti-infective leadership through innovation, responsible use, and collaborative efforts with the medical community.
By combining scientific excellence, a robust portfolio, and stewardship initiatives, we aim to ensure that impactful anti-infective therapies remain accessible, today and for future generations.
